---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-23-018164"
form_type: "8-K"
ticker: "RVPH"
cik: "0001742927"
company_name: "REVIVA PHARMACEUTICALS HOLDINGS, INC."
filed_at: "2023-06-23T23:59:59+00:00"
generated_at: "2026-06-13T18:13:45.472331+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Reviva Pharmaceuticals: Phase 3 RECOVER study enrollment exceeds 80%; topline data expected Q3 2023

## Summary
- Over 80% of patients enrolled in pivotal Phase 3 RECOVER study of brilaroxazine for schizophrenia; enrollment ongoing in US, Europe, Asia.
- Topline data from the ~400-patient placebo-controlled trial expected in Q3 2023.
- Company also reports $5.7M in gross proceeds from Q2 2023 warrant exercises: $4.74M from common warrants at $2.40/share and $0.915M from investor warrants at $4.125/share.

## SEC filing metadata
- accession: 0001437749-23-018164
- form_type: 8-K
- ticker: RVPH
- cik: 0001742927
- company_name: REVIVA PHARMACEUTICALS HOLDINGS, INC.
- filed_at: 2023-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1742927/000143774923018164/0001437749-23-018164-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1742927/000143774923018164/rvph20230621_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-23-018164
- JSON: https://secwatch.observer/filing/0001437749-23-018164.json
- Plain text: https://secwatch.observer/filing/0001437749-23-018164.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.